High risk of breast carcinoma after irradiation of young women with Hodgkin's disease.
Treatment-associated second neoplasms have emerged as a major threat to the continued survival of patients cured of Hodgkin's disease.
In this study, the authors investigated the risk of breast carcinoma in an irradiated Hodgkin's disease population.
One hundred and eleven women younger than 60 years presenting between 1964 and 1984 with Stage I and II Hodgkin's disease who received mantle irradiation were retrospectively analyzed and compared with an age specific population.
Median follow-up was 18 years (range, 10-30 years), and the median age at initiation of therapy was 24 years.
Kaplan-Meier actuarial risks, relative risks (RRs) (the ratio of the observed to the expected cases) with 95% confidence intervals (Cis), and the log rank test for trends were calculated.
Fourteen women developed breast carcinoma : 8 of 33 patients younger than 20 years at the time of irradiation, 5 of 48 patients age 20 to 29 years, and 1 of 30 patients age 30 years or older.
Actuarial calculation predicted a 34.0% (CI, 14.2 - 53.8) risk of breast carcinoma at 25 years after therapy for the youngest group, 22.3% (CI, 4.1-40.5) for the group of intermediate age, and 3.5% (CI, 0-10.1) for the oldest group.
The RR of breast carcinoma was 56 (CI, 23.3-107) for those 19 years or younger at the time of treatment, 7.0 (CI, 2.3-16.4) for those age 20-29 years, and 0.9 (CI, 0-5.3) for those 30 years and older. (...)
Mots-clés Pascal : Hodgkin maladie, Adulte jeune, Homme, Femelle, Radiothérapie, Traitement, Complication, Carcinome, Glande mammaire, Second cancer, Incidence, Epidémiologie, Analyse risque, Etude cohorte, Etude longitudinale, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome, Tumeur maligne, Glande mammaire pathologie
Mots-clés Pascal anglais : Hodgkin disease, Young adult, Human, Female, Radiotherapy, Treatment, Complication, Carcinoma, Mammary gland, Second cancer, Incidence, Epidemiology, Risk analysis, Cohort study, Follow up study, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma, Malignant tumor, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0271847
Code Inist : 002B20E02. Création : 15/07/1997.